QualityStocks.net News – EntreMed Inc. (ENMD) Announces Seasoned VP to Assist in Business Development Initiatives

At www.QualityStocks.Net you can sign up for Quality Stock's Daily Newsletter to find out what Small-Cap and Micro-Cap online Investment Newsletters are interested in, plus hear about the latest news from our clients as well as other publicly traded companies.

We would like to highlight EntreMed Inc. (OTCBB: ENMD). The company is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem® in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis.

In the company’s recent news,

EntreMed Inc. announced Thomas H. Bliss will serve as the company’s senior vice president of corporate and business development.

“It has long been our goal to advance the development of our promising clinical pipeline and to partner those product candidates in order to enhance their value and expedite their progress through the regulatory approval process. Partnering, particularly for ENMD-2076, is a principal goal of the company in 2008. We welcome Tom to EntreMed’s senior management team to help us accomplish this milestone. I am confident that Tom’s extensive knowledge and experience will better position us to aggressively seek partnership opportunities,” James S. Burns, EntreMed’s president and CEO stated in the press release.

Bliss was appointed by the company’s board of directors, in part due to his previous management roles. Bliss has more than 20 years biotechnology business development and healthcare investment banking experience. He previously served as international licensing, licensing operations oversight and the coordination and communication of Amgen’s China/India Research Activities Initiative at Amgen; was responsible for directing all Amgen acquisition activity, including the acquisition of Abgenix; served as vice president of biopharmaceuticals business development at Baxter BioScience; and served in many more roles, including analytical support and investment banking.

“I chose to join EntreMed at this exciting juncture in its development because it allows me to be an integral part of the build-out of what I believe will become a leading biotechnology company. With three oncology products already in the clinic and a rheumatoid arthritis product entering the clinic, the company’s clinical pipeline is ripe for a multitude of partnering and business development opportunities,” stated Bliss. “In addition, EntreMed’s core research and development competency will continue to provide new compounds for potential business development initiatives. I am delighted to lead these efforts and look forward to supporting the company’s growth strategy for developing drugs for oncology and inflammatory diseases.”

About QualityStocks

QualityStocks.net, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks.net is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.